Chronic myeloid leukaemia in the 21st century

Ulster Medical Journal

Volumn 76, Issue 1, 2007, Pages 8-17

  Frazer, Rachel ^a   Irvine, Alexandra E ^a   McMullin, Mary Frances ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANGIOGENESIS INHIBITOR; ANTILEUKEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BORTEZOMIB; CYTARABINE; DASATINIB; HOMOHARRINGTONINE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NILOTINIB; PEGINTERFERON; PEPTIDE VACCINE; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RIBONUCLEIC ACID INHIBITOR; SCH 6636; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MUTATIONAL ANALYSIS; PATIENT MONITORING; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REDUCED INTENSITY CONDITIONING; REVIEW; SIGNAL TRANSDUCTION; STANDARDIZATION; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM;

CYTOGENETIC ANALYSIS; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; LEUKEMIA, MYELOID, CHRONIC; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; WORLD HEALTH;

EID: 33846551857     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Goldman JM, Melo JV. Chronic myeloid leukemia - advances In biology and new approaches to treatment. New Engl J Med 2003;349(15):1451-64.
2. O'Brien S, Tefferi A, Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematology 2004;(1):146-62.
3. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. New Engl J Med 1999; 341(3):164-72.
4. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18 (3):569-84.
5. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001;344(14):1084-6
6. Deiniger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96 (10):3343-56.
7. Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology 2002;(1):111-35.
8. Reid T. Cytogenetics-in colour and digitized. New Engl J Med 2004;350 (16):1597-600.
9. Braziel RM, Shipp MA, Feldman AL, Espina V, Winters W, Jaffe ES, et al. Molecular diagnostics. Hematology 2003;(1):279-93.
10. Schoch C, Schnittgner S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study in 350 cases. Leukemia 2002;16 (1):53-9.
11. Deininger MW. Management of early stage disease. Hematology 2005;(1):174-82.
12. Lowenberg B. Minimal residual disease in chronic myeloid leukemia. New Engl J Med 2003;349(15):1399-401.
13. Beillard E, Pallisgaard N, van der Velden, V.J., Bi W, Dee R, van der Schoot, E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR)- a Europe against cancer program. Leukemia 2003;17 (12):2474-86.
14. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood.2000;95(1):62-6.
15. Gabert J, Beillard E, van der Velden, V.H.J., Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia- a Europe Against Caner Program. Leukemia 2003;17(12):2318-57.
16. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology 2003;17(1):132-52.
17. Mughal TI, Goldman JM. Chronic myeloid leukaemia. In: Encyclopedia of life sciences [electronic resources]. Basingstoke: Nature Publishing Group; 2002. Available from: http://www.mrw.interscience.wiley.com/emrw/ 9780470015902/els/article/a0002181/current/pdf. Accessed November 2006.
18. Tsao AS, Kantarjian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol 2002;119(1):15-24.
19. Druker BJ, Moshe T, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001;344(14):1031-7.
20. Deininger MW, McCreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 2004;18(4):864-71.
21. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9(3):271-81.
22. Peggs K, Mackinnon S. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. New Engl J Med 2003;348(11):1048-50.
23. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. New Engl J Med 2002;346(9):683-93.
24. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003;348(11):994-1004.
25. Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004;9(3):259-70.
26. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002;16(9):1579-83.
27. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003;17(5):829-38.
28. Tauchi T, Ohyashiki K. Molecular mechanisms of resistance to imatinib mesylate. Leuk Res 2004;28(Suppl 1):S39-S45.
29. O'Dwyer ME, Mauro MJ, Blasdel CB, Farnsworth M, Kurilik G, Hsieh YC, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103(2):451-455. [Epub. 2003 Sep 25]
30. Hochhaus A, Hughes TP. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004;18(3):641-56.
31. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistence. Leukemia 2004;18(8):1321-31.
32. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of the BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102(1):276-83. [Epub 2003 Mar 6].
33. Crossman L, O'Brien SG. Imatinib therapy in chronic myeloid leukemia. Hematol Oncol Clin North Am 2004;18(3):605-17.
34. Wang L, Pearson K, Fergusion JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003;120(6):990-9.
35. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify imatinib-treated patients with CML who have BCR-ABL kinase domain mutations. Blood. 2004;104(9):2926-32.
36. Hughes T, Deininger MW, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for harmonising current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28-37.
37. Radich JP, Gooley T, Byrant E, Chauncey T, Clift R, Beppu L, et al. The significance of BCR-ABL molecular detection in chronic myeloid leukemia patients "late", 18 months or more after transplantation. Blood 2001;98(6):1701-7.
38. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002;346(9):645-52.
39. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long term medical outcomes and quality of life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogenic bone marrow transplantation. J Clin Oncol 2002;20(9):2334-43.
40. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20(1):325-34.
41. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-80.
42. Muller MC, Gatterman N, Lahaye T, Deininger W.N., Berndt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ ara-c. Leukemia 2003;17(12):2392-400.
43. Druker BJ. Circumventing resistance to Kinase-inhibitor therapy. New Engl J Med 2006;354(24):2594-6.
44. O'Hare T, Corbin A, Druker BJ. Targeted CML therapy: controlling resistance, seeking cure. Curr Opin Genet Dev 2006;16(1):92-9.
45. O'Hare T, Walters DK, Deiniger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell 2005;7(2):117-9.
46. Weisenberg E, Manley P, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Brit J Canc 2006;94(12):1765-9.
47. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. BCR-ABL resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108(4):1328-33.
48. Kantarjian HM, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib resistant CML and and Philadelphia chromosome positive ALL. New Engl J Med 2006;354(24):2542-51.
49. Manley P, Cowan-Jacob S, Mestan J. Advances in the structural biology, design and clinical development of BCR-ABL kinase inhibitors for the treatment of chronic myeloid leukemia. Biochim Biophys Acta 2005;1754 (1-2):3-13.
50. Frame MC. Src in cancer: degregulation and consequences for cell behviour. Biochim Biophys Acta 2002;1602(2):114-30.
51. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000;103(2):211-25.
52. Shah NP, Tran C, Lee FY, Chen N, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305(5682):399-401.
53. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006;57(2):145-64.
54. Martinelli S, Soverini S, Rosti G, Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2005;19(11):1872-9.
55. Talpaz M, Shah NP, Kantarjian HM, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib resistant Philadelphia chromosome positive leukemias. New Engl J Med 2006;354(24):2531-41.
56. Hampton T. Looking beyond imatinib - next line of targeted drugs for CML shows promise. JAMA 2006;295(4):369-70.
57. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used anti-leukemic agents. Blood 2001;97(7):1999-2007.
58. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreef M, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myeloid leukemia. Blood 1999;93(12):4149-53.
59. Cortes J, O'Brien SG, Giles F, Alvarez RH, Talpaz M, Kantarjian H. Investigational strategies in chronic myelegenous leukemia. Hematol Oncol Clin North Am 2004;18(3):619-639.
60. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, et al. Homoharringtonine and low dose cytarabine in the management of late chronic phase chronic myelogenous leukemia. J Clin Oncol 2000;18(20):3513-21.
61. Du Y, Wang K, Fang H, Li J, Xiao D, Zheng P, et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 2006;107(4):582-90.
62. L. Blood 2000; 95(3):14-22.